The Trump administration urged the court not to take the case, and argued that the president has wide-ranging authority over national security matters.Politicsread more
Sen. Bernie Sanders will announce a plan Monday to forgive the country's $1.6 trillion outstanding student loan tab, intensifying the higher education policy debate in the...Personal Financeread more
The major indexes have stretched to all-time highs and are riding one of their best first halves in decades.Trading Nationread more
Six women are running for president. Five of them are career politicians. Then there's Oprah-approved self-help guru Marianne Williamson.2020 Electionsread more
McDonald's said Monday that it gained market share in the informal eating out category for the first time in five years, thanks to its nationwide launch of fresh beef.Restaurantsread more
As candidates from Elizabeth Warren and Bernie Sanders to John Delaney jockey for position in the 2020 Democratic primary, business issues will come up in the first debates.2020 Electionsread more
The brokerage says that the globe is "one step away" from recession as the world's two largest economies head to the G-20 summit.Marketsread more
President Trump issues an executive order that would pressure insurers, doctors and other providers to disclose more information about health-care prices.Health and Scienceread more
J.P. Morgan analyst Stephen Tusa is sticking to his guns when it comes to General ElectricInvestingread more
The planet of Batuu is now open to all Disneyland theme park guests, but that doesn't mean visiting this galaxy far, far away is going to be easy.Entertainmentread more
A bipartisan team of senators introduce the Dashboard Act to make social media companies disclose the value of user data.Technologyread more
Sarepta Therapeutics CEO Doug Ingram told CNBC on Friday he has a "big ambition" to get the company's Duchenne muscular dystrophy gene therapy to patients as quickly as possible.
He wants Sarepta to be in a position to start dosing children in the approval trial by the end of this year.
"We have a big ambition to potentially be to the community within two years thereafter," Ingram said in an interview with CNBC's Meg Tirrell on "Closing Bell. "
Duchenne muscular dystrophy is a rare genetic disease that causes muscle wasting and can be fatal before patients turn 30. Symptoms usually start in early childhood, usually between 3 and 5 years old. It primarily affects boys but in rare cases can affect girls.
The biopharmaceutical company saw positive preliminary results in a phase 1/2a clinical trial, which sent shares soaring. However, in July, the Food and Drug Administration placed the trial on clinical hold because of a trace amount of DNA fragment found in research-grade third-party supplied plasmid.
"We've had extraordinary early results," Ingram said, but noted that more children need to be treated. The preliminary results were from three children who received the gene therapy.
Ingram said the FDA hold occurred, in part, because of a "manufacturing issue with a supplier" and that Sarepta has "fully responded" to the FDA.
"Our goal and belief is it will be off clinical hold very soon and it shouldn't affect the timing of the things we're going to do," he said.
Ingram hopes to get in front of the FDA in the next 60 days or so to talk about Sarepta's clinical program and the path to get the treatment to the community.
"We are in the lead, but there are other credible programs behind us. And if we can't work fast with a sense of urgency, someone else would do it," he said.
"Our goal is to frankly be fueled by competition to hopefully ensure that we have the most elegant program, we're in the lead and that we can get to this community as fast as possible."
Shares of Sarepta Therapeutics are up more than 200 percent in the last 12 months.
— CNBC's Angelica LaVito contributed to this report.